Scholarlink

Background <p>VEXAS syndrome is a recently described X-linked somatic autoinflammatory syndrome which manifests with exaggerated hyperinflammation, an MDS-like syndrome, and probable immunodeficiency.</p> Objective <p>The objective of this study is to describe the clinical presentation and outcomes of patients with VEXAS syndrome with a focus on immunodeficiency and infectious complications.</p> Methods <p>We performed a retrospective case analysis of VEXAS patients seen in our center and a surrounding immunodeficiency and infectious complications.</p> Results <p>We identified five patients who were diagnosed with VEXAS syndrome between 2021 and 2023. All patients had autoinflammatory syndromes, UBA1 mutations, and characteristic vacuolization on bone marrow biopsy, while none met the criteria for MDS. Infectious complications were identified in all patients at the time of diagnosis. At presentation, patient 1 had <i>Klebsiella pneumoniae</i> bacteremia, patient 2 had disseminated nocardiosis, patient 3 had community acquired pneumonia (CAP), patient 4 had disseminated histoplasmosis, and patient 5 had CAP complicated by cavitary pulmonary lesions. Lymphocyte subset measurements revealed a reduced frequency of circulating effector T and B lymphocytes. All patients received corticosteroids and tocilizumab once infection was treated.</p> Conclusion <p>We identified severe infections in five patients associated with peripheral B and T cell depletion. UBA1-mutations may directly contribute to infection risk through monocyte dysfunction and lymphocyte depletion. Future research should aim to establish the utility of infection prophylaxis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical features of immunodeficiency and severe infection in VEXAS syndrome: a case series

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月17日

查看全文
  • Justin Smith,
  • Dylan Johnson,
  • Mohammed Osman,
  • Jason Soo,
  • Stephanie Keeling

摘要

Background

VEXAS syndrome is a recently described X-linked somatic autoinflammatory syndrome which manifests with exaggerated hyperinflammation, an MDS-like syndrome, and probable immunodeficiency.

Objective

The objective of this study is to describe the clinical presentation and outcomes of patients with VEXAS syndrome with a focus on immunodeficiency and infectious complications.

Methods

We performed a retrospective case analysis of VEXAS patients seen in our center and a surrounding immunodeficiency and infectious complications.

Results

We identified five patients who were diagnosed with VEXAS syndrome between 2021 and 2023. All patients had autoinflammatory syndromes, UBA1 mutations, and characteristic vacuolization on bone marrow biopsy, while none met the criteria for MDS. Infectious complications were identified in all patients at the time of diagnosis. At presentation, patient 1 had Klebsiella pneumoniae bacteremia, patient 2 had disseminated nocardiosis, patient 3 had community acquired pneumonia (CAP), patient 4 had disseminated histoplasmosis, and patient 5 had CAP complicated by cavitary pulmonary lesions. Lymphocyte subset measurements revealed a reduced frequency of circulating effector T and B lymphocytes. All patients received corticosteroids and tocilizumab once infection was treated.

Conclusion

We identified severe infections in five patients associated with peripheral B and T cell depletion. UBA1-mutations may directly contribute to infection risk through monocyte dysfunction and lymphocyte depletion. Future research should aim to establish the utility of infection prophylaxis.